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Canada; and §Toronto General Research Institute, University Health Network, Toronto, Ontario, CanadaABSTRACT Fibroblast growth factor-21 (FGF21) has therapeutic potential for metabolic syndrome due to positive effects on
fatty acid metabolism in liver and white adipose tissue. FGF21 also improves pancreatic islet survival in excess palmitate;
however, much less is known about FGF21-induced metabolism in this tissue. We first confirmed FGF21-dependent activity
in islets by identifying expression of the cognate coreceptor Klothob, and by measuring a ligand-stimulated decrease in
acetyl-CoA carboxylase expression. To further reveal the effect of FGF21 on metabolism, we employed a unique combination
of two-photon and confocal autofluorescence imaging of the NAD(P)H and mitochondrial NADH responses while holding living
islets stationary in a microfluidic device. These responses were further correlated to mitochondrial membrane potential and
insulin secretion. Glucose-stimulated responses were relatively unchanged by FGF21. In contrast, responses to glucose in
the presence of palmitate were significantly reduced compared to controls showing diminished NAD(P)H, mitochondrial
NADH, mitochondrial membrane potential, and insulin secretion. Consistent with the glucose-stimulated responses being
smaller due to continued fatty acid oxidation, mitochondrial membrane potential was increased in FGF21-treated islets by using
the fatty acid transport inhibitor etomoxir. Citrate-stimulated NADPH responses were also significantly larger in FGF21-treated
islets suggesting preference for citrate cycling rather than acetyl-CoA carboxylase-dependent fatty acid synthesis. Overall,
these data show a reduction in palmitate-induced potentiation of glucose-stimulated metabolism and insulin secretion in
FGF21-treated islets, and establish the use of autofluorescence imaging and microfluidic devices to investigate cell metabolism
in a limited amount of living tissue.INTRODUCTIONThe fibroblast growth factor (FGF) family consists of 22
secreted polypeptides divided into seven subfamilies based
on phylogeny, sequence identity, and function (1,2).
Although the majority of FGF-ligands function as para-
crine/autocrine factors, the FGF19 subfamily (FGF15/19,
FGF21, and FGF23) has emerged as a unique class of potent
endocrine factors. Recently, FGF21 has been shown to
exhibit pleiotropic function in regulating obesity, as well
as whole body glucose and lipid metabolism (3). Consis-
tently, FGF21 is transcriptionally regulated by PPARa
(4,5) and appears functionally independent of insulin (6).
Due to these positive effects on metabolic syndrome in
combination with apparently few side-effects, recombinant
FGF21 is being actively explored as a therapeutic (7).
FGF21 signaling occurs through activation of fibroblast
growth factor receptor-1 (FGFR1c) or FGFR2c isoforms,
but uniquely requires coexpression of Klothob (KLB),
a member of the Klotho receptor family (8,9). We have
recently confirmed that FGF21 induces dimerization of
FGFR1c on the plasma membrane of living cells when coex-
pressed with KLB (10). Due to the relative ubiquitous
expression of FGFR1c and FGFR2c, FGF21 tissue-speci-
ficity is dictated by a more limited expression of KLBSubmitted May 22, 2012, and accepted for publication October 18, 2012.
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0006-3495/12/12/2379/10 $2.00(11). Accordingly, KLB is predominantly expressed in
metabolic tissues including white adipose tissue (WAT),
liver, and pancreas (12). We recently demonstrated
FGFR1 activity in mouse pancreatic islets and are presently
unaware of any studies specifically showing expression and
activity of KLB in endocrine pancreas (13). Therefore, our
initial goal was to confirm KLB expression and activity in
pancreatic islets, and consequently measure the effect of
FGF21 activity on islet metabolic responses.
Pancreatic islet b-cells metabolically sense changes in
blood glucose and secrete insulin (14). In b-cells, glycol-
ysis-derived pyruvate enters the tricarboxylic acid (TCA)
cycle equally through pyruvate dehydrogenase (PDH) and
pyruvate carboxylase (PC). PDH-dependent metabolism
generates NADH to increase mitochondrial membrane
potential and ATP production. A rise in the ATP/ADP ratio
closes ATP-sensitive potassium (KATP) channels inducing
membrane depolarization, Ca2þ-influx through voltage-
gated channels, and insulin secretion. However, NADH
via the electron transport chain also generates reactive
oxygen species, which is believed to be a root cause of
b-cell failure. In contrast, NADPH is generated by PC-
dependent metabolism while supporting anaplerosis (refill-
ing) of TCA cycle intermediates and citrate/isocitrate
cycling (15). NADPH provides reducing equivalents to
long-chain fatty acid synthesis and is postulated to modulate
NADH-driven (KATP-dependent) insulin secretion (14).http://dx.doi.org/10.1016/j.bpj.2012.10.028
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system, which protects b-cells by scavenging reactive
oxygen species. Therefore, metabolism through PDH
(NADH-dependent) and PC (NADPH-dependent) differen-
tially impacts glucose-stimulated insulin secretion and
b-cell survival. In this study, we use autofluorescence
imaging of NAD(P)H and mitochondrial NADH in living
islets to infer FGF21-induced changes in PDH- and PC-
dependent metabolism (16–18).
b-cells initially show significantly greater glucose-stimu-
lated insulin secretion in the presence of fatty acids due to
large metabolic flux and glucose-stimulated reduction in
fatty acid oxidation. Glucose stimulates efflux of citrate
from mitochondria, which is converted to malonyl CoA to
both inhibit fatty acid transport through carnitine palmitoyl-
transferase-1 (CPT1) and act as a substrate for long-chain
fatty acid synthesis. However, chronic inhibition of fatty
acid oxidation in the presence of fatty acids is not handled
well by b-cells and eventually results in dissipation of the
glucose-stimulated response. FGF21 has been shown to
protect ex vivo pancreatic islets from palmitate-induced
toxicity through ERK1/2 and Akt-dependent signaling
mechanisms (19). Due to the link between b-cell metabo-
lism and toxicity, we hypothesized that FGF21 reduces the
toxic effects of excess palmitate by modulating glucose-
stimulated PDH metabolism. We therefore confirmed
KLB expression in islets and further examined the effect
of FGF21 on glucose- and palmitate-induced metabolism.
Furthermore, these studies demonstrate the use of autofluor-
escence imaging and microfluidic device trapping to explore
islet metabolism in a limited amount of live tissue with high
spatial and temporal resolution.MATERIALS AND METHODS
Pancreatic islet isolation and tissue culture
Animal procedures were approved by the Animal Care Committee of the
University Health Network, Toronto, Ontario, Canada in accordance with
the policies and guidelines of the Canadian Council on Animal Care
(Animal Use Protocol #1531). Pancreatic islets were isolated from 8- to
12-week-old C57BL6 male mice by using collagenase digestion (Roche,
Mississauga, Canada) (20,21). Islets were subsequently cultured in full
RPMI 1640 medium supplemented with 11 mM glucose, 10% fetal bovine
serum, and 5 U/ml penicillin-streptomycin.Palmitate preparation
Palmitic acid (Sigma-Aldrich Canada Ltd., Oakville, Canada) was dis-
solved to palmitate in 0.1 M NaOH at 70C. Fatty acid free-bovine serum
albumin (BSA) (BioShop, Burlington, Canada) was dissolved in ddH2O by
shaking at 4C. Palmitate was subsequently conjugated to fatty acid free-
BSA by mixing at a ratio of 1 mM palmitate:1% BSA at 60C. The final
BSA-conjugated palmitate solution was diluted to 0.4 mM in subsequent
preparations of either standard islet culture media or imaging media
(125 mM NaCl, 5.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 10 mM
HEPES, and the indicated glucose concentration, pH 7.4).Biophysical Journal 103(11) 2379–2388Polymerase chain reaction analysis
Oligonucleotide primers were designed to amplify the KLB cDNA
sequence (N-terminal sequence from aa119 using 50-ACCTGTGCCAAA
CCCATG-30 and 50-GCTGTCTGCGTTTGTTCTG-30, or the C-terminal
sequence from aa339 using 50-AGATGAGTGGTTTCTTCTC-30 and 50-
TCCATCGGTTATGAAGGAAT-30). The master mix (total volume 25 ml)
was composed of 1 ml mouse islet cDNA (10 ng/ml), 12.5 ml GoTaq Green
Mixture, 9.5 ml nuclease free water, and 1 ml of each primer (10 mM final
concentration). An MJ Research PTC-200 Peltier Thermal Cycler was
used with the following cycling parameters: 94C for 30 s, 52C for
1 min, and 72C for 1 min (30 cycles). The housekeeping gene glyceralde-
hyde-3-phosphate dehydrogenase (GADPH) was amplified as a positive
control using identical cycling parameters (50-ATCGAGCTCATCCCAT
CACCATCTTCCAGG-30 and 50-ACATCTAGAGCCATCACGCCACAGT
TTCCC-30), and all reactions included nuclease-free water as a negative
control.Immunofluorescent detection of KLB
Freshly isolated islets were dissociated to single cells using Accutase as
described previously (13). Single cell populations were allowed to adhere
to poly-L-lysine-coated Labtech dishes for 2 h. Dispersed cells and intact
islets were subsequently fixed with 2% paraformaldehyde and nonspecifi-
cally blocked in phosphate buffered saline containing 5% normal donkey
serum and 0.1% Triton X-100 (2 h; room temperature (RT)). The dispersed
cells were incubated with goat antimouse KLB antibody (AF2619, R&D
Systems, Minneapolis, MN, 1:500, 4C overnight) and donkey antigoat
Alexa568 antibody (Invitrogen, Grand Island, NY, 1:1000, RT for 1 h),
and subsequently with guinea pig antiinsulin antibody (Dako, Glostrup,
Denmark, 1:500, RT for 1 h) and goat antiguinea pig Alexa 488 antibody
(Invitrogen, 1:1000, RT for 1h). Islets were incubated with goat antimouse
KLB antibody (4C overnight) and donkey antigoat Alexa 568 antibody
(RT for 1 h). Whole islets were imaged as 3–5 z-sections using the 20
0.95 NA lens and 543-nm excitation of a Zeiss LSM710 confocal to create
extended focus maximum projection images.Western immunoblotting
Purified islets in culture (P35dishes)were stimulatedwithFGF21 (100ng/ml)
for 48h. Isletswere subsequently handpicked intomicrofuge tubes containing
islet media and collected by centrifugation (3000 rpm; 3 min). Islets were re-
suspended in lysis buffer (1% Triton X-100, 100 mMNaCl, 50mM HEPES,
5% glycerol, 1 mM sodium vanadate, and protease inhibitor mix (Roche);
1 ml/islet) and lysed on ice for 45 min. Whole-islet protein lysates (20–
80 islets/lane) were separated by 8% SDS-PAGE and transferred to Trans-
Blot nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were
blocked by incubating with 5% nonfat dry milk powder in Tris-buffered
saline-Tween 20 (TBS-T) for 1 h at RT. Proteins of interest were detected
by overnight incubation at 4C in 5% BSA/TBS-T containing one of the
followingprimary antibodies: acetyl-CoAcarboxylase (ACC) (Cell Signaling
Technology (CST), Danvers, MA, 1:1000) or b-actin ((CST); 1:1000). Blots
were subsequently incubated with antirabbit peroxidase-conjugated antibody
((CST), 1:2000) diluted in 5% milk/TBS-T (45min RT), and proteins of
interest were detected by enhanced chemiluminescence (Pierce, Thermo
Fisher, Rockford, IL).Redox autofluorescence imaging
Pancreatic islets were loaded into microfluidic devices before autofluores-
cence imaging as described previously (16,17,22). Briefly, NAD(P)H
imaging was performed using a 705 nm Ti:Saph laser attenuated to
~3 mW (Coherent, Santa Clara, CA), and the 40 1.3 NA oil immersion
objective lens of a Zeiss LSM710 microscope. Epifluorescencewas directed
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Chroma, Bellows Falls, VT) to an external nondescanned detector (16,17).
All autofluorescence images were collected ~20 mm into the tissue to focus
on the b-cells inside the core of the islet. NAD(P)H autofluorescence is
from the combined signal of NADH and NADPH, with the majority of the
signal from the mitochondrial pools. Lipoamide dehydrogenase (LipDH)
autofluorescence imaging was performed on the same sample using sequen-
tial 458 and 488 nm excitation, a 505 nm long pass filter, a pinhole size of
3.09 AU, and pixel dwell time of 12.6 ms (17). Changes in LipDH redox
state were measured using the 458:488 nm ratio due to red shifting
compared to other cellular flavoproteins and are directly proportional to
mitochondrial NADH (mNADH) levels (23,24). The 458:488 nm ratio
does not isolate the absolute LipDH redox state, but rather can be used to
measure relative changes in the redox state. We have reported here the
LipDH(mNADH) responses (458:488 nm ratio) indexed to values achieved
using pharmacological treatments that maximize and minimize mitochon-
drial NADH. Islets were routinely imaged 3 min posttreatment with
2 mM FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) and
the resulting 458:488 nm ratio was defined as the minimum (0%) LipDH
(mNADH) redox index. Islets were also routinely imaged 5 min posttreat-
ment with 3 mM NaCN þ 20 mM glucose and the resulting 458:488 nm
ratio was defined as the maximum (100%) LipDH(mNADH) redox index.Image analysis
Themean intensity of islets in each image (NAD(P)H (705 nm), LipDH (458
and 588 nm)was obtained from20 small circular regions of interest that were
randomly selected while avoiding nuclear regions, saturated pixels, and
nonresponsive lipofuscin deposits. Five regions distant to the islet were
also measured to obtain the average background intensity in each image.Insulin secretion
Islets (20–40) were cultured as indicated and then handpicked into micro-
fuge tubes for equilibration in 2 mM glucose-imaging buffer at 37C.
The islets were subsequently stimulated as indicated for 40 min intervals.
Supernatant was collected from microtubes before addition of the succeed-
ing stimulation. After collection of the final set of supernatants, total
islet insulin content was released by 1% Triton X-100. Fractional total
insulin was quantified using a sandwich insulin ELISA assay (Millipore,
Billerica, MA).FIGURE 1 KLB expression and FGF21-dependent responses in pancre-
atic islets. (A) The cDNA from two separate mouse islet preparations (IsletsRhodamine123 imaging
Islets were suspended in 2 mM glucose-imaging buffer and incubated in the
presence of Rh123 (10 mg/ml; 30 min at 37C). Islets were subsequently
imaged using a Zeiss LSM710 confocal using the 514-nm laser line,
525–655-nm bandpass filter, pinhole size of 1.73 AU, and a pixel dwell
time of 12.6 ms.
1 and 2) were amplified using oligonucleotide primers designed to recog-
nize the N- (KLB-front) and C-terminal (KLB-end) ends of KLB. GAPDH
cDNAwas amplified to ensure sample integrity, and water was included as
a no-DNA negative control. (B) Pancreatic islets were fixed and immuno-
fluorescently labeled using an antibody specific for the extracellular domain
of KLB (left panels). Dispersed inlet cells were also immunofluorescentlyData analysis
Data are expressed as mean5 S.E.M. All statistical calculations were per-
formed with two-tailed ANOVA and the Tukey post hoc test.labeled with both KLB (red) and insulin (green) (right panels). Immuno-
staining in the absence of primary antibody (No Primary) was included
as a negative control. Scale bar represents 50 mm. (C) A representative
Western immunoblot reveals a reduction in mouse islet ACC protein level
when incubated in the presence of FGF21 (48 h; 100 ng/ml). Membranes
were stripped and reprobed for b-actin as a loading control. (D) The
summarized fold-ACC response normalized to b-actin for control and
FGF21-treated islets. Data shown represent the mean 5 S.E.M. for islets
from five independently assayed and treated mice. (*P < 0.05).RESULTS
Pancreatic islet KLB expression and FG21-
responses
We have previously shown that murine b-cells express
active fibroblast growth factor receptor-1 (FGFR1), part ofthe required FGF21 signaling complex (13). To determine
whether murine islets express KLB, the recognized corecep-
tor for FGF21, we examined islet mRNA transcript expres-
sion using oligonucleotide primers specific to the N- and
C-terminal ends of KLB (Fig. 1 A). We further examined
KLB protein expression by immunofluorescence in isolated
islets and islets dispersed to single cells (Fig. 1 B). These
data show significant KLB expression in islets and more
specifically in insulin-positive b-cells. We also observed
a fraction of KLB-positive cells that were insulin negative
(red cells that were not green) suggesting either the exis-
tence of another population of KLB-positive islet cells or
contamination from exocrine cells. Combined, these data
reveal that murine islet b-cells express detectable levels of
KLB mRNA and protein. Previous studies have shownBiophysical Journal 103(11) 2379–2388
2382 Sun et al.that FGF21-activity regulates expression of ACC in the liver
and WAT. We therefore examined ACC expression in
FGF21-treated islets (100 ng/ml) by Western immunoblot
and observed a significant decrease (~50%) in islet ACC
protein expression levels compared to controls (Fig. 1, C
and D). Overall, these data show that murine islets express
KLB coreceptor and are responsive to FGF21. The reduc-
tion in islet ACC expression is consistent with responses
observed in other tissues, and suggests that FGF21 modu-
lates fatty acid metabolism in islets (8,25–27).FIGURE 2 Autofluorescence imaging of living pancreatic islets in a mi-
crofluidic device. Pancreatic islets were routinely brought into microfluidic
devices before imaging the two-photon NAD(P)H and confocal LipDH
(mNADH) responses. (A) A representative microfluidic device is shown
flooded with food coloring to highlight the inlet and outlet tubing, main
channel, dam wall, and reservoir. The device is composed of polydimethyl-
siloxane bonded to a glass coverslip, which provides an optimized optical
window. Inlet- and outlet-tubing were used to bring islets into the microflui-
dic device and for removing effluent, respectively. Once 3 to 10 islets were
loaded into the device, the inlet tubing was capped and flow was initiated
from the on-chip reservoir to the outlet tubing. Islets captured in the device
were held against the coverslip while media was allowed to flow past. (B) A
representative islet stimulated with 2 mM glucose was imaged using two-
photon 710 nm excitation and confocal 488 and 488 nm excitation (top
row). This same islet was subsequently imaged after treatment with 3 mM
sodium cyanide for 5 min (bottom row). Scale bar represents 20 mm. (C)
The summarized NAD(P)H and 458:488 nm image ratio responses to
2mMglucose, 3mMcyanide, and 2mMFCCP. TheNAD(P)H data is plotted
as the fold-response to 2 mM glucose. The 458:488 nm ratio plotted as arbi-
trary units (left axis) is a readout of the LipDH(mNADH) redox state. These
pharmacological treatments induce maximal and minimal cellular redox
state and were subsequently used to index the LipDH or mitochondrial
NADH response (LipDH(mNADH)) (right axis). Data represent the pooled
response from 13 and 30 islets harvested from 2 and 3 mice on separate days
for the sodium cyanide and FCCP data, respectively (*P < 0.01).Autofluorescence imaging of microfluidic device-
trapped pancreatic islets
Pancreatic islets isolated from animals are of limited size
and quantity, which increases the complexity of traditional
biochemical assays. To quantitatively measure the cellular
redox state in a limited amount of tissue with high temporal
resolution, we used autofluorescence imaging of living
pancreatic islets trapped in a microfluidic device (Fig. 2).
A custom-built microfluidic device allowed the introduction
of islets via inlet tubing (Fig. 2 A). Islets brought into the
100 mm tall  600 mm wide main channel were stopped
from moving completely through the device by a dam
wall. In this setup, the islets were held stationary against
the glass coverslip for optimal subcellular resolution
imaging. The islets were subsequently treated with nutrients
and/or pharmacological agents by simply changing the
reservoir well, and the responses imaged in real time on
an inverted confocal microscope. In these studies, we
routinely imaged the autofluorescence of living pancreatic
islets using two-photon 710-nm excitation of NAD(P)H
and confocal 458- and 488-nm excitation of flavoproteins
(Fig. 2 B). Islets were initially treated with 2 mM glucose
(Fig. 2 B; top panels) to establish a low redox potential,
followed by exposure to sodium cyanide to increase cellular
redox potential (Fig. 2 B; bottom panels). A significant rise
in NAD(P)H intensity (two-photon 710 nm) and drop in
flavoprotein intensity (458- and 488-nm images) by sodium
cyanide was distinctly evident by imaging. We have previ-
ously shown that the ratio of the 458- and 488-nm images
(458:488 nm ratio) quantitatively isolates the redox
responses of LipDH, a flavoprotein in equilibrium with the
mitochondrial NADH (mNADH) pool (17). Treating islets
with sodium cyanide or FCCP maximally reduces or
oxidizes the cellular redox state, respectively (Fig. 2 C).
The data shown in Fig. 2 C reveal consistent changes in
the fold NAD(P)H responses (Fig. 2 C; left graph) and
458:488 nm image ratio (Fig. 2 C; right graph). These phar-
macological treatments were used to subsequently index the
nutrient-induced responses of LipDH(mNADH) (Fig. 2 C;
right axis). These data set the dynamic range for the
LipDH(mNADH) index of our microscope, and further
show the redox imaging and microfluidic methods used to
tease apart metabolic responses of islets.Biophysical Journal 103(11) 2379–2388Glucose-stimulated NAD(P)H responses
A previous study showed FGF21 protects islets from palmi-
tate-induced toxicity (19). We postulated that FGF21
Redox Imaging of Pancreatic Islets 2383protects islets by modulating glucose-stimulated metabo-
lism. To quantitatively measure the effect of FGF21 on islet
metabolism, we imaged the glucose-stimulated NAD(P)H
response using two-photon microscopy (16,28) (Fig. 3).
Islets showed a significant glucose-stimulated increase in
NAD(P)H intensity with exposure to increasing glucose
levels (Fig. 3 B). By quantifying NAD(P)H intensity in
a number of islets, we observed similar responses from all
islets examined over most of the glucose dose-response
examined. However, in the presence of excess glucose
(20 mM), FGF21-treated islets showed a statistically
smaller NAD(P)H response compared to controls (Fig. 3
B). These data show that FGF21 does not dramatically
modify islet glucose-stimulated metabolism with only
moderate differences revealed at supraphysiological levels
of glucose. Chronic fatty acid stimulation induces b-cell
stress. To measure the effect of chronic fatty acid-induced
stress on islet function, we further explored maintenance
of glucose-stimulated NAD(P)H responses after culture
for an additional 24 h in media containing palmitate
(0.4 mM) in the presence and absence of FGF21 (Fig. 3
C). A more dynamic NAD(P)H response was observed in
FGF21-treated islets compared to controls at all concentra-
tions of glucose examined, consistent with a previous study
(19) and indicative of improved islet survival.Glucose-stimulated NAD(P)H and LipDH(mNADH)
responses
Metabolism of glycolysis-derived pyruvate can lead to
PDH-stimulated production of NADH and PC-stimulated
production of NADPH. To determine whether FGF21 modu-
lates glucose-stimulated PDH-dependent (NADH) and
PC-dependent (NADPH) metabolism, we compared the
two-photon NAD(P)H and mitochondrial NADH responses
(Fig. 4). LipDH is in direct equilibrium with mitochondrial
NADH, therefore the LipDH(mNADH) redox index
measures changes in the mitochondrial NADH signal for
comparison to the two-photon NAD(P)H response
(17,23,24). Islets were cultured in FGF21 (100 ng/ml) for
48 h before imaging responses to glucose, glucose in the
presence of palmitate, or citrate. No difference was observed
in the two-photon NAD(P)H response of control and
FGF21-treated islets at 10 mM glucose. However, we again
observed a slightly smaller NAD(P)H response in FGF21-
treated islets exposed to 20 mM glucose compared to
controls (Fig. 4 A). In contrast, the LipDH(mNADH) redox
index was no different at all concentrations of glucose
examined (Fig. 4 B). These imaging data are therefore
consistent with no difference in the glucose-stimulated
mitochondrial NADH (PDH-dependent) response of
FGF21-treated islets, and only a small decrease in the
NADPH (PC-dependent) response observed in the presence
of excess glucose. Furthermore, FGF21 does not induce
changes in the mRNA expression of proteins related to mito-chondrial uncoupling or citrate cycling suggesting that the
autofluorescence responses are due to metabolic output
rather than mitochondrial energetics (see the Supporting
Material, Fig. S1).
In a reaction rate limited by ACC, citrate from the TCA
cycle is converted to malonyl-CoA to act as an inhibitor
of fatty acid oxidation. Reduced expression of ACC protein
in FGF21-treated islets therefore suggested modulation of
glucose-stimulated CPT1-closure and fatty acid oxidation.
To measure the effect of fatty acids on glucose-induced
metabolism, we measured glucose-stimulated responses in
the presence of palmitate (Fig. 4). Glucose stimulated
a significant increase in aggregate NAD(P)H in both control
and FGF21-treated islet islets in the presence of palmitate
(Fig. 4 A). This response was accompanied by a small rise
in the LipDH(mNADH) redox index in control islets that
was unexpectedly absent in FGF21-treated islets (Fig. 4
B). These data are consistent with FGF21-treated islets
having a limited mitochondrial NADH response to glucose
in the presence of fatty acids, consistent with reduced
PDH activity in FGF21-treated islets.
Independent of ACC, citrate is also metabolized to a-ke-
toglutarate in the cytoplasm producing NADPH. To assess
changes in islet metabolism upstream of ACC, we further
examined the NAD(P)H and LipDH(mNADH) responses
of islets in response to 20 mM citrate (Fig. 4). Citrate caused
no change in NAD(P)H intensity in control islets, but
a significant increase in the intensity of FGF21-treated islets
(Fig. 4 A). By comparing the two-photon NAD(P)H and
LipDH(mNADH) responses (Fig. 4 B), citrate induced
greater production of NADPH in FGF21-treated islets than
in control islets (a rise in NAD(P)H not observed in control
islets that is again accompanied by similar mitochondrial
NADH responses). These data are consistent with FGF21
altering islet metabolism to favor NADPH production
from citrate, and suggest citrate cycling rather than metabo-
lism to malonyl-CoA. These data also suggest that changes
in islet metabolism induced by FGF21 go beyond simply
regulating ACC expression and will need to be explored
further to reveal the entire metabolic outcome and
mechanism.Mitochondrial membrane potential and insulin
secretion
Redox imaging suggested that palmitate did not potentiate
glucose-induced mitochondrial NADH response in
FGF21-treated islets. However, autofluorescence imaging
provides an indirect measure of the metabolite-stimulated
responses. We therefore aimed to see whether these changes
in redox response translated to similar downstream
responses in mitochondrial energetics and insulin secretion
(Fig. 5). To determine whether the LipDH(mNADH)
responses translated to mitochondrial energetics, Rhoda-
mine 123 (Rh123) intensity was imaged and quantified asBiophysical Journal 103(11) 2379–2388
FIGURE 3 Glucose-stimulated NAD(P)H responses. Pancreatic islets
were cultured for 48 h in full RPMI media 1640 at 11 mM glucose in the
absence (control) and presence (FGF21) of FGF21. Palmitate (0.4 mM)
was added to a separate batch of islets after 24 h to induce palmitate
toxicity. All islets were subsequently incubated in imaging media contain-
ing 2 mM glucose at 37C (minimum 30 min), and loaded into microfluidic
Biophysical Journal 103(11) 2379–2388
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(Fig. 5 A). Increased levels of glucose stimulated a decrease
in Rh123 intensity that was similar in control and FGF21-
treated islets and reflects a comparable increase in mito-
chondrial membrane potential in all islets (Fig. 5, A and
B). However, FGF21-treated islets showed a significantly
smaller glucose-stimulated decrease in Rh123 intensity
compared to controls in the presence of palmitate
(Fig. 5 B) that was consequently ablated by the coaddition
of etomoxir (an inhibitor of CPT1-dependent fatty acid
transport). These data suggest that the reduced mitochon-
drial NADH and membrane potential responses of FGF21-
treated islets are due to fatty acid transport and oxidation.
To determine whether the LipDH(mNADH) and mitochon-
drial membrane responses translated to downstream func-
tion, the fractional insulin secretion of islets in response to
glucose in the presence and absence of palmitate was exam-
ined (Fig. 5 C). Consistent with observed LipDH(mNADH)
and mitochondrial membrane potential responses, no differ-
ence in glucose-stimulated insulin secretion was evident
between control and FGF21-treated islets. Similarly, no
difference was observed in the palmitate-induced insulin
response between control and FGF21-treated islets.
However, consistent with previous studies, glucose-stimu-
lated insulin secretion of control islets was significantly
greater in the presence of palmitate as compared to
glucose-alone. In contrast, FGF21-treated islets stimulated
with glucose secreted similar levels of insulin regardless
of the presence of palmitate, and significantly less than
control islets in palmitate. Overall, these data reveal that
FGF21-treated islets exhibit glucose-stimulated responses
similar to control islets; however, FGF21-treated islets do
not exhibit palmitate-induced potentiation of insulin secre-
tion further confirming the NAD(P)H and LipDH(mNADH)
imaging data.DISCUSSION
Recombinant FGF21 is actively being explored as a thera-
peutic for type 2 diabetes due to potent effects in lowering
the blood glucose and lipids in mice. The majority of studies
to date explore mechanisms of action in liver andWATusing
classical biochemical methods. However, the effect of
FGF21 on pancreatic islets has been given significantlydevices on the microscope stage to image the two-photon NAD(P)H
response to varied glucose levels (as indicated). (A) Representative images
of NAD(P)H autofluorescence for a device-immobilized islet at 2 and
20 mM glucose. (B) The summarized mitochondrial NAD(P)H intensities
throughout the glucose dose-response from islets cultured in the absence
of palmitate. Data represent the pooled response from 20 to 30 islets har-
vested from 3 mice on separate days. (C) The summarized mitochondrial
NAD(P)H intensities throughout the glucose dose-response from islets
cultured for 24 h in the presence of palmitate (0.4 mM). Data represent
the pooled response from 15 to 20 islets harvested from 3 mice on separate
days. (*P < 0.05).
AB
FIGURE 4 Glucose-stimulated NAD(P)H and LipDH(mNADH)
responses. Pancreatic islets were cultured for 48 h in full RPMI media
1640 at 11 mM glucose in the absence (control) and presence (FGF21) of
FGF21. Islets were subsequently incubated in imaging media containing
2 mM glucose or 2 mM glucose þ 0.4 mM palmitate (37C; minimum of
30 min) followed by loading into microfluidic devices on the microscope
stage to image the glucose-stimulated NAD(P)H and LipDH (mNADH)
redox index responses. All responses were measured at least 20 min after
subsequent addition of the indicated substrates. (A) The summarized fold
NAD(P)H response of mitochondrial regions from islets exposed to glucose
(2, 10, and 20 mM), high glucose (20 mM) in the presence of palmitate, and
low glucose (2 mM) in the presence of citrate. (B) The summarized
LipDH(mNADH) redox index for the same islets shown in (A). The LipDH
response (458:488 nm intensity ratio) was indexed to pharmacological
treatments that minimize and maximize mitochondrial NADH reduction.
Data were collected from control islets (n ¼ 21 (glucose), 14 (palmitate),
and 21 (citrate)) and FGF21-treated islets (n ¼ 28 (glucose), 14 (palmitate)
22 (citrate)) harvested from mice on 3 separate days. (* and # indicate P <
0.05 compared to 2 mM and 2mM þ FGF21, respectively).
Redox Imaging of Pancreatic Islets 2385less attention particularly considering a previous report
showing increased islet survival of palmitate-induced
toxicity (19). This may in part be due to the inherent diffi-
culty of working with pancreatic islets due to limited sizeand availability. The current study explored the basic mech-
anisms of FGF21-activity by using a combination of micro-
fluidic device capture and quantitative autofluorescence
imaging. Our goal was to determine whether FGF21 treat-
ment of islets modulated islet metabolism, or more specifi-
cally, reduced PDH-dependent metabolism due to a direct
link between NADH production and cell stress. Our unique
combination of methods allowed us to gain mechanistic
insight into the interaction of glucose and fatty acid mito-
chondrial metabolism in a limited amount of living tissue.
FGFR1c and KLB form the cognate receptor complex for
FGF21 (11). We previously demonstrated FGFR1 expres-
sion and activity in mouse islets (13). Our data now confirms
coexpression of KLB in islets consistent with the endocrine
pancreas having the capacity to be FGF21-responsive.
FGF21-treated islets also showed a decrease in ACC expres-
sion similar to responses observed in liver and WAT (25,27).
ACC is the rate limiting enzyme for converting citrate into
malonyl-CoA, a substrate for long-chain fatty acid synthesis
and potent inhibitor of mitochondrial transport and oxida-
tion of fatty acids. These data were collected to confirm
a response to FGF21 in pancreatic islets. Glucolipotoxicity
models suggest that long-chain fatty acid synthesis induces
b-cell stress and that enhancing fatty acid oxidation is
a mechanism to reduce this stress (29,30). Consistent with
a role for FGF21 in stimulating islet survival, we also
observed a more dynamic glucose-stimulated NAD(P)H
response in treated islets cultured for 24 h in palmitate.
We therefore postulate that FGF21 signaling decreases islet
ACC expression as one compensatory mechanism to reduce
palmitate-induced toxicity. Further studies will be required
to obtain a more global picture of the metabolic changes
induced by FGF21 in pancreatic islet b-cells.
Using autofluorescence imaging of living islets, we
subsequently examined the effect of FGF21 on the
glucose-stimulated NAD(P)H and mitochondrial NADH
responses. FGF21-treated islets showed only moderate
differences in glucose-stimulated NAD(P)H and mitochon-
drial NADH responses compared to controls. In contrast,
more significant differences were revealed in the presence
of palmitate where FGF21-treated islets showed reduced
glucose-stimulated mitochondrial NADH. Of importance,
we correlated this autofluorescence data with complemen-
tary methods including measuring decreased mitochondrial
membrane potential and insulin secretion. These readouts
are all consistent with reduced PDH-dependent production
of NADH in FGF21-treated islets when in the presence of
palmitate. Critically, mitochondrial membrane potential
was restored in FGF21-treated islets by the CPT1 inhibitor
etomoxir suggesting PDH-dependent NADH is somehow
limited by fatty acid oxidation. A more direct measurement
of fatty acid oxidation will be needed to confirm these indi-
rect data.
Similar to the Randle model, our data suggest that
continued fatty acid oxidation in FGF21-treated isletsBiophysical Journal 103(11) 2379–2388
FIGURE 5 Glucose-stimulated changes in mitochondrial membrane
potential and insulin secretion. Pancreatic islets were cultured for 48 h in
full RPMI media 1640 supplemented with 11 mM glucose in the absence
(control) and presence (FGF21) of FGF21. Islets were subsequently used
for measurement of mitochondrial membrane potential or measuring
glucose stimulated insulin secretion. (A) Islets were incubated in imaging
Biophysical Journal 103(11) 2379–2388
2386 Sun et al.inhibits glucose oxidation (31). An essential component of
the Randle model is that a fatty acid-induced accumulation
of acetyl CoA in the fasted state inhibits PDH activity
through phosphorylation by PDH kinase (31). Our data are
consistent with similar regulation of PDH-activity; however,
in contrast to Randle’s work, our observations were made
in the presence of excess glucose (the fed state). Excess
glucose stimulates mitochondrial efflux of citrate to subse-
quently decrease fatty acid oxidation by closure of CPT1
by ACC-dependent production of malonyl CoA. We postu-
late that continued transport and oxidation of fatty acids in
FGF21-treated islets, even in the presence of excess glucose,
limits PDH-dependent metabolism of glycolysis-derived
pyruvate. In effect, FGF21-treated islets maintain PDH
activity in a fasted state despite the presence of glucose
and palmitate. We further postulate that continued fatty
acid oxidation in the presence of glucose lessens toxicity
associated with glucose oxidation through PDH. Future
studies are required to explore the regulation of PDH
activity by citrate/malonyl CoA production and CPT1 trans-
port, and will critically depend on the temporal resolution
provided by autofluorescence imaging of islets in a micro-
fluidic device.
The reduction in insulin secretion from FGF21-treated
islets is a phenotype generally not considered beneficial in
type 2 diabetes. However, reducing glucose-stimulated
mitochondrial NADH and membrane potential would also
contribute to the long-term survival of islets (19). Mitochon-
drial NADH induces reactive oxygen species (ROS) due to
leakage of electrons at complex I and III of the electron
transport chain. This leakage is particularly prevalent during
state IV respiration, defined as a state of excess metabolite
(high NADH) and minimal ADP (32). Limiting mitochon-
drial NADH would therefore be expected to decrease ROS
production. We observed a significant glucose-stimulatedmedia containing 2 mM glucose (37C for 1 h) followed by addition of
Rh123 (10 mg/ml). Labeled islets were loaded into microfluidic devices
on the microscope stage for imaging. Representative images are shown of
the same Rh123-labeled control islet subsequently stimulated with 2 mM
glucose (5 min), 2 mM glucose þ 0.4 mM palmitate (25 min), and
20 mM glucose þ 0.4 mM palmitate (5 min). (B) The summarized data
from islets in glucose alone (2, 10, and 20 mM), and glucose in the presence
of 0.4 mM palmitate (20 mM glucose, and 20 mM glucose þ 10mM eto-
moxir) is reported as fold Rh123 intensity (arbitrary units, AU) relative
to 2 mM glucose. Data was collected from control (n ¼ 20–25) and
FGF21-treated (n ¼ 20–25) islets harvested from mice on 3 separate
days. (*P < 0.05). (C) Islets were further incubated in imaging media con-
taining 2 mM glucose (37C for 30 min) and effluent was sequentially
collected following 1 h incubations with the indicated nutrients. Sample
supernatant (effluent) was carefully collected and assayed. The fractional
insulin response from control and FGF21-treated islets in response to
glucose alone (2, 10, and 20 mM glucose) and glucose in the presence of
0.4 mM palmitate (Control þ 0.4 mM palmitate and FGF21 þ 0.4 mM
palmitate) are shown. Data were normalized to total insulin content
collected post islet permeabilization with 1% triton X-100. Data shown
are summarized from the islets harvested from 4 to 8 mice on independent
days. (*P < 0.05).
Redox Imaging of Pancreatic Islets 2387NADPH response in FGF21-treated islets. NADPH provides
reducing potential to glutathione and thereby benefits ROS
scavenging. Mitochondrial ROS has recently been impli-
cated as an amplifying mechanism for insulin secretion
and may also in part account for the reduction in glucose-
stimulated insulin secretion observed in FGF21-treated
islets (33,34). Overall, a reduction in mitochondrial ener-
getics would limit ROS production and insulin secretion,
whereas an increase in NADPH would reduce the effect of
ROS and ultimately improve long-term survival.
Due to the reduced mitochondrial membrane potential
and insulin secretion found in FGF21-treated islets, we
also explored UCP2 and NNT expression as an alternative
mechanism of uncoupling mitochondrial energetics rather
than reduced PDH-dependent production of NADH (see
the Supporting Material). UCP2 has been shown to have
a protective role in islets, although this role is still debated
(35,36). NNT converts NADH to NADPH resulting in
mild uncoupling and has also been shown to play a protec-
tive role in b-cells (37–39). Our data showed no change in
mRNA expression of UCP2 and NNT, inconsistent with
increasing mitochondrial uncoupling in the presence of
palmitate. However, our data do not discount posttransla-
tional regulation of the activity of these proteins. A number
of alternative mechanisms also exist for uncoupling mito-
chondria and reducing mitochondrial NADH including the
mitochondrial permeability transition pore (MPTP). The
MPTP increases permeability to ions such as Ca2þ resulting
in depletion of mitochondrial membrane potential. The
MPTP is generally considered to have a role in pathophys-
iology (40); however, MPTP has also been shown to act in
a low conductance state triggered by stress (41). A varied
number of mechanisms and techniques will need to be
considered to determine the effective role of uncoupling
rather than PDH-dependent metabolism in controlling mito-
chondrial energetics in FGF21-treated islets.
In summary, we have used a unique strategy to measure
FGF21-stimulated changes in isletmetabolismby combining
autofluorescence imaging with microfluidic capture. These
studies revealed changes in glucose-stimulated NAD(P)H
and mitochondrial NADH when concurrently exposed to
palmitate. Our data show pancreatic islets treated with
FGF21 modify glucose-stimulated responses only at supra-
physiological levels or in the presence of excess fatty acids.
Using multiple methods to follow up on our initial discovery,
we further revealed that FGF21-treated islets do not show
palmitate-induced potentiation of glucose-stimulated mito-
chondrial energetics and insulin secretion. All changes
induced by FGF21 to islet metabolism were consistent with
reduced PDH-dependent metabolism stimulated by fatty
acid stimulation; however, further studies are required to
validate this conclusion. Nevertheless, to our knowledge,
these studies suggest a novel paradigm that enhancing fatty
acid oxidation may be protective against glucolipotoxicity
due to inhibition of PDH-dependent metabolism.SUPPORTING MATERIAL
Additional methods, results, and one figure are available at http://www.
biophysj.org/biophysj/supplemental/S0006-3495(12)01181-2.
Funding was provided by the Canadian Institutes of Health Research
(CIHR) (NMD106997) and the Heart and Stroke Foundation of Ontario
(HSFO) (NA6591). The microscope used in these studies was purchased
through a Canada Foundation Innovation (CFI) Leaders Opportunity
Fund (18301). These funding sources had no role in the study design or
other aspects of the manuscript.REFERENCES
1. Itoh, N., and D. M. Ornitz. 2004. Evolution of the Fgf and Fgfr gene
families. Trends Genet. 20:563–569.
2. Ornitz, D. M., and N. Itoh. 2001. Fibroblast growth factors. Genome
Biol. 2:3005, REVIEWS.
3. Kharitonenkov, A. 2009. FGFs and metabolism. Curr. Opin. Pharma-
col. 9:805–810.
4. Badman, M. K., P. Pissios, ., E. Maratos-Flier. 2007. Hepatic fibro-
blast growth factor 21 is regulated by PPARalpha and is a key mediator
of hepatic lipid metabolism in ketotic states. Cell Metab. 5:426–437.
5. Inagaki, T., P. Dutchak,., S. A. Kliewer. 2007. Endocrine regulation
of the fasting response by PPARalpha-mediated induction of fibroblast
growth factor 21. Cell Metab. 5:415–425.
6. Kharitonenkov, A., T. L. Shiyanova,., A. B. Shanafelt. 2005. FGF-21
as a novel metabolic regulator. J. Clin. Invest. 115:1627–1635.
7. Kharitonenkov, A., and A. B. Shanafelt. 2008. Fibroblast growth
factor-21 as a therapeutic agent for metabolic diseases. BioDrugs.
22:37–44.
8. Ogawa, Y., H. Kurosu,., M. Kuro-o. 2007. BetaKlotho is required for
metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci.
USA. 104:7432–7437.
9. Suzuki, M., Y. Uehara, ., T. Imamura. 2008. betaKlotho is required
for fibroblast growth factor (FGF) 21 signaling through FGF receptor
(FGFR) 1c and FGFR3c. Mol. Endocrinol. 22:1006–1014.
10. Ming, A. Y., E. Yoo,., J. V. Rocheleau. 2012. Dynamics and Distri-
bution of Klothob (KLB) and fibroblast growth factor receptor-1
(FGFR1) in living cells reveal the fibroblast growth factor-21
(FGF21)-induced receptor complex. J. Biol. Chem. 287:19997–20006.
11. Kurosu, H., M. Choi,., M. Kuro-o. 2007. Tissue-specific expression
of betaKlotho and fibroblast growth factor (FGF) receptor isoforms
determines metabolic activity of FGF19 and FGF21. J. Biol. Chem.
282:26687–26695.
12. Ito, S., S. Kinoshita,., Y. I. Nabeshima. 2000. Molecular cloning and
expression analyses of mouse betaklotho, which encodes a novel Klo-
tho family protein. Mech. Dev. 98:115–119.
13. Kilkenny, D. M., and J. V. Rocheleau. 2008. Fibroblast growth factor
receptor-1 signaling in pancreatic islet beta-cells is modulated by the
extracellular matrix. Mol. Endocrinol. 22:196–205.
14. Jitrapakdee, S., A. Wutthisathapornchai, ., M. J. MacDonald. 2010.
Regulation of insulin secretion: role of mitochondrial signalling. Dia-
betologia. 53:1019–1032.
15. Ying, W. 2008. NADþ/NADH and NADPþ/NADPH in cellular func-
tions and cell death: regulation and biological consequences. Antioxid.
Redox Signal. 10:179–206.
16. Rocheleau, J. V., W. S. Head,., D. W. Piston. 2002. Pancreatic islet
beta-cells transiently metabolize pyruvate. J. Biol. Chem. 277:30914–
30920.
17. Rocheleau, J. V., W. S. Head, and D. W. Piston. 2004. Quantitative
NAD(P)H/flavoprotein autofluorescence imaging reveals metabolic
mechanisms of pancreatic islet pyruvate response. J. Biol. Chem. 279:
31780–31787.Biophysical Journal 103(11) 2379–2388
2388 Sun et al.18. Sankar, K. S., B. J. Green,., J. V. Rocheleau. 2011. Culturing pancre-
atic islets in microfluidic flow enhances morphology of the associated
endothelial cells. PLoS ONE. 6:e24904.
19. Wente, W., A. M. Efanov, ., J. Gromada. 2006. Fibroblast growth
factor-21 improves pancreatic beta-cell function and survival by activa-
tion of extracellular signal-regulated kinase 1/2 and Akt signaling path-
ways. Diabetes. 55:2470–2478.
20. Scharp, D. W., C. B. Kemp,., P. E. Lacy. 1973. The use of ficoll in the
preparation of viable islets of langerhans from the rat pancreas. Trans-
plantation. 16:686–689.
21. Stefan, Y., P. Meda,., L. Orci. 1987. Stimulation of insulin secretion
reveals heterogeneity of pancreatic B cells in vivo. J. Clin. Invest.
80:175–183.
22. Lam, A. K., P. N. Silva, ., J. V. Rocheleau. 2012. Quantitative
imaging of electron transfer flavoprotein autofluorescence reveals the
dynamics of lipid partitioning in living pancreatic islets. Integr. Biol.
(Camb). 4:838–846.
23. Kunz, W. S. 1988. Evaluation of electron-transfer flavoprotein and
alpha-lipoamide dehydrogenase redox states by two-channel fluorim-
etry and its application to the investigation of beta-oxidation. Biochim.
Biophys. Acta. 932:8–16.
24. Kunz, W. S., and F. N. Gellerich. 1993. Quantification of the content of
fluorescent flavoproteins in mitochondria from liver, kidney cortex,
skeletal muscle, and brain. Biochem. Med. Metab. Biol. 50:103–110.
25. Coskun, T., H. A. Bina,., A. Kharitonenkov. 2008. Fibroblast growth
factor 21 corrects obesity in mice. Endocrinology. 149:6018–6027.
26. Palou, M., T. Priego, ., C. Pico´. 2008. Sequential changes in the
expression of genes involved in lipid metabolism in adipose tissue
and liver in response to fasting. Pflugers Arch. 456:825–836.
27. Xu, J., D. J. Lloyd,., M. M. Ve´niant. 2009. Fibroblast growth factor
21 reverses hepatic steatosis, increases energy expenditure, and
improves insulin sensitivity in diet-induced obese mice. Diabetes.
58:250–259.
28. Blinova, K., R. L. Levine, ., R. S. Balaban. 2008. Mitochondrial
NADH fluorescence is enhanced by complex I binding. Biochemistry.
47:9636–9645.Biophysical Journal 103(11) 2379–238829. Prentki, M., E. Joly,., R. Roduit. 2002. Malonyl-CoA signaling, lipid
partitioning, and glucolipotoxicity: role in beta-cell adaptation and
failure in the etiology of diabetes. Diabetes. 51(Suppl 3):S405–S413.
30. Prentki, M., and C. J. Nolan. 2006. Islet beta cell failure in type 2 dia-
betes. J. Clin. Invest. 116:1802–1812.
31. Randle, P. J. 1998. Regulatory interactions between lipids and carbohy-
drates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev.
14:263–283.
32. Chance, B., and G. R. Williams. 1955. Respiratory enzymes in oxida-
tive phosphorylation. IV. The respiratory chain. J. Biol. Chem. 217:
429–438.
33. Pi, J., Y. Bai,., S. Collins. 2007. Reactive oxygen species as a signal
in glucose-stimulated insulin secretion. Diabetes. 56:1783–1791.
34. Rebelato, E., F. Abdulkader,., A. R. Carpinelli. 2011. Control of the
intracellular redox state by glucose participates in the insulin secretion
mechanism. PLoS ONE. 6:e24507.
35. Chan, C. B., M. C. Saleh,., M. B. Wheeler. 2004. Uncoupling protein
2 and islet function. Diabetes. 53(Suppl 1):S136–S142.
36. Zhang, C. Y., G. Baffy,., B. B. Lowell. 2001. Uncoupling protein-2
negatively regulates insulin secretion and is a major link between
obesity, beta cell dysfunction, and type 2 diabetes. Cell. 105:745–755.
37. Freeman, H., K. Shimomura, ., F. M. Ashcroft. 2006. Nicotinamide
nucleotide transhydrogenase: a link between insulin secretion, glucose
metabolism and oxidative stress. Biochem. Soc. Trans. 34:806–810.
38. Freeman, H., K. Shimomura, ., F. M. Ashcroft. 2006. Nicotinamide
nucleotide transhydrogenase: a key role in insulin secretion. Cell
Metab. 3:35–45.
39. Freeman, H. C., A. Hugill, ., R. D. Cox. 2006. Deletion of nicotin-
amide nucleotide transhydrogenase: a new quantitive trait locus
accounting for glucose intolerance in C57BL/6J mice. Diabetes. 55:
2153–2156.
40. Lemasters, J. J., T. P. Theruvath,., A. L. Nieminen. 2009. Mitochon-
drial calcium and the permeability transition in cell death. Biochim.
Biophys. Acta. 1787:1395–1401.
41. Zoratti, M., and I. Szabo`. 1995. The mitochondrial permeability transi-
tion. Biochim. Biophys. Acta. 1241:139–176.
